Apart from one recommendation – to create a government compensation program for Third World nationals harmed by trials intended to benefit First World subjects – US Presidential Commission for the Study of Bioethical Issues, chaired by Dr. Amy Gutmann, the president of the University of Pennsylvania, did not get much beyond vague notions of community engagement and transparency. But, with 70% of all drug trials now conducted by private companies, such concepts won’t go very far towards tougher regulation.
除了建议为第三世界国家建立一个政府基金项目，补偿他们为服务第一世界人们而进行的实验而受到的伤害之外，由宾夕法尼亚大学校长艾美·古德曼博士主持的美国总统生物伦理问题研究委员会在社区参与以及执行透明度等模糊概念上并没有多少收获。不过，考虑到目前70%的药物实验都是由私人机构执行的现实，这些概念也不会带来什么严厉的管制。